Although there are a number of treatment options for depression, some people experience depression that doesn’t respond to treatment. This is commonly referred to as treatment resistant depression (TRD). 

Sheppard Pratt is conducting a clinical research study of an investigational medication for TRD. This outpatient double blind study will evaluate the efficacy, safety, and tolerability of esketamine nasal spray administered as monotherapy versus placebo in adults with treatment-resistant depression.

Eligibility

You may be eligible to participate if you:

  • Are 18 years of age or older
  • Have been diagnosed with major depressive disorder (MDD)
  • Have not responded to at least 2 different anti-depressant treatments

PI: Scott Aaronson, MD

Sponsor: Janssen Research & Development, LLC

Contact: To participate in this study or for more information, contact Sam Rudow at srudow@sheppardpratt.org or call 410-938-3126